Laura Saarelainen1,2, Anna-Maija Tolppanen2,3, Marjaana Koponen1,2, Antti Tanskanen4,5,6, Jari Tiihonen4,6,7, Sirpa Hartikainen1,2,8, Heidi Taipale1,2,4. 1. Kuopio Research Centre for Geriatric Care, University of Eastern Finland, Kuopio, Finland. 2. School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 3. Research Centre for Comparative Effectiveness and Patient Safety, University of Eastern Finland, Kuopio, Finland. 4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 5. Impact Assessment Unit, National Institute for Health and Welfare, Helsinki, Finland. 6. Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland. 7. Stockholm County Council, Stockholm, Sweden. 8. Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland.
Abstract
OBJECTIVE: To investigate the risk of death associated with new benzodiazepine and related drug (BZDR) use in a nationwide cohort of persons with Alzheimer disease (AD). METHODS: The register-based MEDALZ cohort, including all community-dwelling Finns diagnosed with AD during 2005 to 2011 (n = 70 718), was used. Clinically verified AD diagnoses were obtained from the Special Reimbursement Register. Drug use periods were modeled from BZDR purchases, derived from the Prescription Register. To study new users, persons who had any BZDR use during the year preceding the AD diagnosis were excluded. For each person initiating BZDR use (n = 10 380), 2 nonusers (n = 20 760) were matched on age, gender, and time since AD diagnosis. The outcome was 180-day mortality, and BZDR use was compared with nonuse with Cox regression. Multivariable analyses were adjusted for Charlson comorbidity index, socioeconomic position, hip fractures, psychiatric disorders, substance abuse, stroke, and other psychotropic drug use. RESULTS: During the follow-up, 5 excess deaths per 100 person-years occurred during BZDR use in comparison to nonuse, and mortality rates were 13.4 (95% confidence interval [CI], 12.2-14.5) and 8.5 (95% CI, 7.9-9.1), respectively. Benzodiazepine and related drug use was associated with an increased risk of death (adjusted hazard ratio = 1.4 [95% CI, 1.2-1.6]), and the association was significant from the initiation of use. Benzodiazepine use was associated with an increased risk of death, whereas benzodiazepine-related drug use was not. CONCLUSIONS: Benzodiazepine and related drug use was associated with an increased risk of death in persons with AD. Our results support treatment guidelines stating that nonpharmacological approaches should be the first-line option for symptomatic treatment of AD.
OBJECTIVE: To investigate the risk of death associated with new benzodiazepine and related drug (BZDR) use in a nationwide cohort of persons with Alzheimer disease (AD). METHODS: The register-based MEDALZ cohort, including all community-dwelling Finns diagnosed with AD during 2005 to 2011 (n = 70 718), was used. Clinically verified AD diagnoses were obtained from the Special Reimbursement Register. Drug use periods were modeled from BZDR purchases, derived from the Prescription Register. To study new users, persons who had any BZDR use during the year preceding the AD diagnosis were excluded. For each person initiating BZDR use (n = 10 380), 2 nonusers (n = 20 760) were matched on age, gender, and time since AD diagnosis. The outcome was 180-day mortality, and BZDR use was compared with nonuse with Cox regression. Multivariable analyses were adjusted for Charlson comorbidity index, socioeconomic position, hip fractures, psychiatric disorders, substance abuse, stroke, and other psychotropic drug use. RESULTS: During the follow-up, 5 excess deaths per 100 person-years occurred during BZDR use in comparison to nonuse, and mortality rates were 13.4 (95% confidence interval [CI], 12.2-14.5) and 8.5 (95% CI, 7.9-9.1), respectively. Benzodiazepine and related drug use was associated with an increased risk of death (adjusted hazard ratio = 1.4 [95% CI, 1.2-1.6]), and the association was significant from the initiation of use. Benzodiazepine use was associated with an increased risk of death, whereas benzodiazepine-related drug use was not. CONCLUSIONS:Benzodiazepine and related drug use was associated with an increased risk of death in persons with AD. Our results support treatment guidelines stating that nonpharmacological approaches should be the first-line option for symptomatic treatment of AD.
Authors: Kathryn Richardson; George M Savva; Penelope J Boyd; Clare Aldus; Ian Maidment; Eduwin Pakpahan; Yoon K Loke; Antony Arthur; Nicholas Steel; Clive Ballard; Robert Howard; Chris Fox Journal: Health Technol Assess Date: 2021-01 Impact factor: 4.014
Authors: Kathryn Richardson; Yoon K Loke; Chris Fox; Ian Maidment; Robert Howard; Nicholas Steel; Antony Arthur; Penelope J Boyd; Clare Aldus; Clive Ballard; George M Savva Journal: BMC Med Date: 2020-11-24 Impact factor: 8.775
Authors: Esther S Oh; Paul B Rosenberg; Gail B Rattinger; Elizabeth A Stuart; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos Journal: J Am Geriatr Soc Date: 2020-12-31 Impact factor: 5.562
Authors: Heidi Taipale; Hanna Särkilä; Antti Tanskanen; Terhi Kurko; Tero Taiminen; Jari Tiihonen; Reijo Sund; Annamari Tuulio-Henriksson; Leena Saastamoinen; Jarmo Hietala Journal: JAMA Netw Open Date: 2020-10-01
Authors: Simon Jc Davies; David Rudoler; Claire de Oliveira; Anjie Huang; Paul Kurdyak; Andrea Iaboni Journal: J Psychopharmacol Date: 2022-02-01 Impact factor: 4.562